We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $268.94 which represents a slight increase of $1.84 or 0.69% from the prior close of $267.1. The stock opened at $269.33 and touched a low ...

The Food and Drug Administration approved Amgen Inc ‘s AMGN Lumakras (sotorasib) in combination with Vectibix (panitumumab) ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of Amgen Inc. AMGN inched 0.24% higher to $264.00 Monday, on what proved to be an all-around favorable trading session ...